Eli Casdin founded Casdin Capital in 2011 and serves as Chief Investment Officer. Casdin Capital engages as a team of productive investor-partners, helping to fuel the visions of industry leaders by adding expertise and experience to their funding. Focused on emergent technologies in life sciences for more than two decades, Eli has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the life sciences and healthcare industries. Prior to founding Casdin Capital, he served as vice president at Alliance Bernstein’s thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there he co-authored the 2011 black book The Dawn of Molecular Medicine, detailing the then-early yet accelerating wave of innovations transforming healthcare and creating opportunity for investors in areas from testing to targeted medicine, diagnostics, and industrial agriculture. Earlier, he worked as a financial analyst at Bear Stearns and Cooper Hill Partners, a healthcare-focused investment firm. Eli earned a BS from Columbia University and an MBA from Columbia Business School. Today, he serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups, and academic institutes including Rockefeller University, the New York Genome Center, and The Columbia University School of General Studies.